Profusa Inc. Common Stock (PFSA)

FairStock Score: 13/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

I look first for a business that earns money and can defend it. Profusa is a medical-device developer with the Lumee Oxygen Platform and a glucose platform, but the filed record shows a fragile enterprise. FY2025, ended 2025-12-31, produced a net loss of $35.8M; fiscal Q3 2025 produced a net loss of $22.2M; fiscal Q2 2026 produced a net loss of $8.8M. Revenue is n/a in most filed periods; FY2024 showed $100,000, so there is little evidence of commercial scale. FY2023 did show net income of $1.2M, which is why FairStock’s Lynch category is TURNAROUND — loss in latest year after earlier profits — but one earlier profit does not create a moat. The balance-sheet signals are poor. FairStock’s Piotroski F-Score is 2/9 and Altman Z-Score is -263.84, both pointing to severe financial stress. Trailing free cash flow is -$20.4M against a $2.7M market cap at the 2026-10-26 close, a FCF yield of -747.5%. At that price, the market is not paying for current earnings power; it is paying an option value on future funding and commercial success. The 52-week range of $0.08–$30.00 shows how speculative the shares have been. Graham would demand a margin of safety in assets or earnings; here both are hard to establish, with P/B N/A and P/E 0.00 as FairStock calculations. I see no numerical margin of safety and no proven durable moat. It could work if technology and sales finally scale, but the figures describe a cash-consuming development company, not a bargain.

In plain English: Profusa makes tiny sensors designed to monitor oxygen and glucose in the body. The business looks very weak today: it has reported large losses and little or no reported revenue in many periods. At $0.78 per share, the price looks speculative rather than cheap based on the current numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-26 close · note generated 2026-10-28 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer